National Pharmaceutical Technology & Research Development (PTRD) "Gold Award" !

We are pleased to announce that EirGasun 150mg has won the "Gold Award" at this year’s 22^nd National Pharmaceutical Technology & Research Development (PTRD) Awards! This is the highest affirmation of the innovation and determined efforts of EirGenix’s team and proof of the excellent quality of EirGenix’s products.

EirGasun is a trastuzumab biosimilar for the treatment of patients with HER2-positive early-stage breast cancer, metastatic breast cancer and gastric cancer. It is the first biosimilar to be developed, manufactured and successfully marketed in Taiwan. In 2023, it has received approval from Taiwan’s Ministry of Health and Welfare (May),

EMA CHMP (September), and Taiwan’s National Health Insurance (October).

This is a very important milestone for Taiwan's biotechnology industry as well as cancer patients all over the world. EirGenix is one step closer to reaching its goal of improving the quality of life for patients through the development of safe and effective biosimilars that are both high-quality and affordable.

 #Eirgenix  #EirGasun  #Biosimilar #PTRD